GlassScriptPhysician profile
Masood Jilani
NPI 1861682734
$2,949.14
in general payments reported to CMS, 2019-2025
24 companies · $1,040 in 2025
The $1,040 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.47 · 2020: $15.67 · 2022: $204 · 2023: $781 · 2024: $863 · 2025: $1,040.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $499.58 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $474.70 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Lundbeck LLC | $282.31 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $217.76 | 2023-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Indivior INC. | $200.81 | 2019-2024 | Perseris |
| Alkermes, INC. | $171.66 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $163.85 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $145.10 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $108.68 | 2023-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $85.53 | 2023-2024 | Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $84.55 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $79.79 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $72.71 | 2022-2025 | Trintellix |
| Tris Pharma INC | $61.76 | 2022-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $55.46 | 2023-2024 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $50.72 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $40.33 | 2024 | Qelbree |
| Corium, LLC | $36.40 | 2022-2023 | Azstarys |
| Luye Pharma (USA) LTD. | $33.48 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $23.02 | 2022 | |
| Janssen Biotech, INC. | $16.42 | 2023 | |
| Collegium Pharmaceutical, INC. | $15.52 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $15.30 | 2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $13.70 | 2023 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Masood Jilani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.